Clario to deliver industry leading Randomization, Trial Supply and Management SaaS for new partnership with IDDI
Use of Clario RTSM will help IDDI launch clinical studies faster and more cost effectively in more markets
- New partnership will provide IDDI’s clients with a configurable, agile, purpose built RTSM system that accommodates simple to highly complex studies without custom code
- RTSM supports rapid study start-up and provides the functionality required to meet the ever-increasing level of complexity of many clinical trials
- Clario RTSM accommodates the full spectrum of protocol designs, from simple studies that require only randomization through complex studies that involve dosing, titration, and multiple cohorts
PHILADELPHIA, PA – June 22, 2022 – Clario, a technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and site-based clinical trials, today announced that its Randomization, Trial Supply Management (RTSM) Software as a Service Business is partnering with IDDI to enable software delivery to their customer base.
RTSM supports rapid study start-up and provides the functionality required to meet the ever-increasing level of complexity of many clinical trials. Clario offers the industry’s only purpose-built, end-to-end, configurable RTSM solution that reduces cost and increases speed of deployment. Together, Clario’s Interactive Response Technology (IRT) and Trial Supply Optimization (TSO) covers the full cycle of supply management from planning and forecasting, through inventory management.
“We are very excited that IDDI has chosen Clario RTSM to randomize and manage supply in their sponsors’ studies. Clario RTSM is configurable software, that allows analysts to configure studies rather than programmers. Combined with the integrated trial supply management software, IDDI will be able to deliver a perfectly managed supply plan in each study or program of studies. We are very pleased to support IDDI and their sponsors to optimize their clinical programs,” commented Guy Crossley, President of Clario eClinical Software.
“We chose Clario RTSM because it gives us the ability to help our sponsors in a way that no other software can. The configurable nature of the software will allow us to bring studies to market much faster than our competitors and will also allow us to manage mid-study changes more efficiently, with less effort. In addition, we will be able to continue combining our RTSM expertise with our statistical expertise to ensure that studies are configured in the most reliable and efficient way for our clients. We are thrilled with our strategic decision,” said Serge Bodart, Chief Commercial Officer at IDDI.
About IDDI
IDDI is an expert clinical data services and high-level strategic consulting contract research organization (CRO), providing agile clinical trials services for pharmaceutical, biotech, and medical device/diagnostic companies. With over 30 years and more than 1300 clinical trials of experience, IDDI is a valuable partner in the design, conduct and analysis in clinical research through optional study design, state-of the-art data management services and systems, and innovative statistical methodology that help achieve time saving and cost-effective clinical trial processes. IDDI helps sponsors make better data-driven decisions, mitigate risks and improve the quality of study submissions. Discover more on: www.iddi.com.
About Clario
Clario is a leading technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized and site-based trials, our deep scientific expertise, global scale, and the broadest endpoint technology platform in the industry, allows our partners to transform lives. Clario’s solutions have been powering hybrid and decentralized clinical trials (DCT) for over 15 years, enabling sponsors to collect high-quality endpoint data from any modality or location, all while improving the patient experience and diversity. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion and respiratory endpoints. With 30 facilities in nine countries, Clario’s global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory for over 5m patients in 120 countries. Our innovation has been transforming clinical trials for 50 years.
Clario Media Contact
Duncan Cantor
Sr. Director, Corporate Communications
[email protected]